AllPeptides.eu - Advanced Peptide Research
    Research-use-only hub
    2 variants

    Educational protocol hub

    CJC-1295 DAC: protocol variants and reconstitution resources

    Educational hub for CJC-1295 DAC, grouping 2 available protocol variants with links to the exact dosage and reconstitution pages.

    What this hub covers

    This page groups the available CJC-1295 DAC protocol variants so readers can choose the exact vial-size guide without mixing formats.

    Reconstitution workflow

    Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.

    Research-only context

    All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.

    Available protocol variants

    Choose the exact guide you want to view.

    CJC-1295 DAC

    2mg

    CJC-1295 DAC dosing protocols leverage the unique albumin-binding technology of this long-acting GHRH analog, which extends its half-life to approximately 6–8 days. By stimulating pulsatile growth hormone (GH) release while preserving natural GH rhythms, CJC-1295 DAC can increase GH levels 2–10 fold and IGF-1 levels 1.5–3 fold in human studies. This protocol outlines a once-weekly subcutaneous approach.

    View protocol

    CJC-1295 DAC

    5mg

    CJC-1295 DAC is a long-acting synthetic GHRH analog. The DAC (Drug Affinity Complex) modification reversibly binds to albumin, extending its half-life to ~6–8 days. By stimulating pituitary GHRH receptors, it increases GH secretion and circulating IGF-1 in a dose-dependent manner. This protocol outlines a twice-weekly subcutaneous approach.

    View protocol

    Related research resources

    Internal links that help readers and search engines understand this peptide topic cluster.

    References

    1. J Clin Endocrinol Metab — Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults
      View Source
    2. Jetté L et al. Endocrinology 2005 — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
      View Source
    3. Growth Hormone & IGF Research — Activation of the GH/IGF-1 axis by CJC-1295
      View Source
    4. Body Composition and Quality of Life in GH-Deficient Adults — Body composition and quality of life in adults with GH deficiency
      View Source
    5. Physiology of Growth Hormone Secretion During Sleep — Physiology of growth hormone secretion during sleep
      View Source
    6. J Clin Endocrinol Metab (2006) — Prolonged stimulation of GH and IGF-1 by CJC-1295
      View Source
    7. J Clin Endocrinol Metab (2006) — Pulsatile GH secretion during continuous stimulation by CJC-1295
      View Source
    8. Am J Physiol (2006) — CJC-1295 normalizes growth in a GHRH knockout mouse
      View Source
    9. StatPearls (NCBI) — Physiology, Growth Hormone
      View Source
    10. Ayuk J et al. Postgrad Med J 2006 — Growth hormone and its disorders.
      View Source

    Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu